Genomic Valley Biotech Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	3.56	0.15	6.48	-0.09	-5.59
Depreciation & Amortization	0.03	0.01	0.08	0.84	1.89
Loss (Gain) From Sale of Assets	-	-	-	-4.19	-
Other Operating Activities	-0.04	-0.02	2.22	-3.33	0.57
Change in Accounts Receivable	3.16	-3.13	-22.17	0.65	0.38
Change in Inventory	-2.84	-	-	-	1.24
Change in Other Net Operating Assets	-3.59	2.78	5.6	-15.17	16.36
Operating Cash Flow	0.27	-0.2	-7.79	-21.29	14.85
Operating Cash Flow Growth	-	-	-	-	239.44%
Capital Expenditures	-0.09	-	-	-	-15.79
Sale of Property, Plant & Equipment	-	-	14.79	53.46	-
Investment in Securities	0.17	-0.17	-	-	-
Other Investing Activities	0.04	0.02	0.43	-16.78	-0
Investing Cash Flow	0.12	-0.15	15.22	36.68	-15.79
Long-Term Debt Issued	-	-	-	-	0.68
Long-Term Debt Repaid	-	-	-7.05	-15.47	-
Net Debt Issued (Repaid)	-	-	-7.05	-15.47	0.68
Financing Cash Flow	-	-	-7.05	-15.47	0.68
Miscellaneous Cash Flow Adjustments	-	0	-	-	-
Net Cash Flow	0.39	-0.35	0.39	-0.09	-0.26
Free Cash Flow	0.18	-0.2	-7.79	-21.29	-0.95
Free Cash Flow Margin	2.09%	-12.16%	-28.60%	-3017.82%	-45.45%
Free Cash Flow Per Share	0.06	-0.07	-2.55	-6.84	-0.31
Cash Income Tax Paid	0.85	-	-	-	-
Levered Free Cash Flow	2.6	-4.6	-1.7	-18.68	-13.86
Unlevered Free Cash Flow	2.6	-4.6	-1.7	-18.41	-12.75
Change in Working Capital	-3.27	-0.35	-16.57	-14.52	17.97

Source: S&P Global Market Intelligence. Standard template. Financial Sources.